NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Sun X, Patnode CD, Williams C, et al. Interventions to Improve Patient Adherence to Hepatitis C Treatment: Comparative Effectiveness [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Dec. (Comparative Effectiveness Reviews, No. 91.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Interventions to Improve Patient Adherence to Hepatitis C Treatment: Comparative Effectiveness

Interventions to Improve Patient Adherence to Hepatitis C Treatment: Comparative Effectiveness [Internet].

Show details

Appendix CExcluded Studies

Excluded Codes:

E1: Study relevance: not a study of Hepatitis C Treatment Adherence

E2: No relevant outcomes

E3: Duration of follow-up

E4: Population

E4a: Population not undergoing combination therapy

E4b: >5% of population age <18

E5: Study design

E6: Precedes search period (2001)

E7: Physician initiated tx discontinuation or dose reduction

E8: Efficacy trial

1.
Alavian SM, Aalaei-Andabili SH. Education by a Nurse Increases the Adherence to Therapy in Chronic Hepatitis C Patients. Clin Gastroenterol Hepatol. 2012;10(2):203. KQ1E5, KQ3E5, KQ4E5. [PubMed: 21839708]
2.
Arase Y, Suzuki F, Suzuki Y, et al. Side effects of combination therapy of peginterferon and ribavirin for chronic hepatitis-C. Internal Medicine. 2007;46(22):1827–32. KQ2E1. [PubMed: 18025763]
3.
Baran RW, Bhor M, Dietz B, et al. Poor adherence to treatment with pegylated interferon/ribavirin in patients with chronic hepatitis C infection is associated with detrimental health outcomes. Hepatology; 60th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting; 2009; Boston, MA. 2009. p. 653A. KQ2E2.
4.
Brau N, Bini EJ, Currie S, et al. Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin*. Journal of Viral Hepatitis. 2006 Apr;13(4):242–49. KQ2E4a. [PubMed: 16611190]
5.
Chainuvati S, Khalid SK, Kancir S, et al. Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders. Journal of Viral Hepatitis. 2006 Apr;13(4):235–41. KQ2E4a. [PubMed: 16611189]
6.
Chen T-M, Huang P-T, Wen C-F, et al. Reappraisal of the importance of mutations in the NS5A-PKR-binding domain of hepatitis C-1b virus in the era of optimally individualized therapy. Journal of Viral Hepatitis. 2011;18(2):119–28. KQ2E8. [PubMed: 20236237]
7.
Chun DS. An assessment of support group participation on depression and adherence in veterans with hepatitis C. 63 ed. US: ProQuest Information & Learning; 2002. KQ3E4a.
8.
Costiniuk CT, Mills E, Cooper CL. Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus. Canadian Journal of Gastroenterology. 2008;22(4):376–80. KQ3E4a, KQ4E4a. [PMC free article: PMC2662895] [PubMed: 18414712]
9.
De Careaga BO. Predictive factors for response to treatment of chronic hepatitis C. Annals of Hepatology. 2006;5(Suppl 1):S24–28. KQ2E1.
10.
Delgado JS, Baumfeld Y, Novack V, et al. Efficacy of combined pegylated interferon and ribavirin therapy in Jewish patients of Israel suffering from chronic hepatitis C. Hepatol Int. 2011 May 8 KQ2E8. [PubMed: 21553307]
11.
Dore GJ, Hellard M, Matthews GV, et al. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology. 2010 Jan;138(1):123–35. KQ2E4. [PMC free article: PMC2813391] [PubMed: 19782085]
12.
Ebner N, Wanner C, Winklbaur B, et al. Retention rate and side effects in a prospective trial on hepatitis C treatment with pegylated interferon alpha-2a and ribavirin in opioid-dependent patients. Addiction Biology. 2009 Apr;14(2):227–37. KQ1E1, KQ2E1, KQ3E1, KQ4E1. [PubMed: 19291011]
13.
El Makhzangy H, Esmat G, Said M, et al. Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. J Med Virol. 2009 Sep;81(9):1576–83. KQ2E8. [PubMed: 19626613]
14.
Evon DM, Esserman DA, Ramcharran D, et al. Social support and clinical outcomes during antiviral therapy for chronic hepatitis C. Journal of Psychosomatic Research. 2011 Nov;71(5):349–56. KQ2E2. [PMC free article: PMC3197215] [PubMed: 21999979]
15.
Falasca K, Ucciferri C, Mancino P, et al. Use of epoetin beta during combination therapy of infection with hepatitis c virus with ribavirin improves a sustained viral response. J Med Virol. 2010 Jan;82(1):49–56. KQ1E1, KQ3E1. [PubMed: 19950239]
16.
Fumaz CR, Munoz-Moreno JA, Ballesteros AL, et al. Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfected patients. AIDS Care. 2007 Jan;19(1):138–45. KQ2E2. [PubMed: 17129869]
17.
Gardenier D, Wisnivesky J, McGinn LK, et al. Hepatitis C treatment completion in individuals with psychiatric comorbidity and depression. Gastroenterol Nurs. 2011 Mar;34(2):102–06. KQ3E1. [PubMed: 21455042]
18.
Gazdag G, Horvath G, Szabo O, et al. Difficulties with interferon treatment in former intravenous drug users. Brazilian Journal of Infectious Diseases. 2011 Apr;15(2):163–66. KQ2E2. [PubMed: 21503405]
19.
Gleason OC, Yates WR, Isbell MD, et al. An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry. 2002 Mar;63(3):194–98. KQ3E1. [PubMed: 11926717]
20.
Gonzalez SA. Consensus interferon: tailored therapy and the impact of adherence. Digestive Diseases & Sciences. 2011 Mar;56(3):631–34. KQ1E4, KQ2E4, KQ3E4, KQ4E4. [PubMed: 21259073]
21.
Grebely J, Matthews GV, Hellard M, et al. Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. Journal of Hepatology. 2011;55(1):76–85. KQ2E4. [PMC free article: PMC3117933] [PubMed: 21145855]
22.
Huang JF, Yu ML, Huang CF, et al. The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis c patients with hepatocellular carcinoma post curative therapies - a multicenter prospective trial. Journal of Hepatology. 2011 Feb;54(2):219–26. KQ2E8. [PubMed: 21056500]
23.
Huckans MS, Loftis JM, Blackwell AD, et al. Interferon alpha therapy for hepatitis C: treatment completion and response rates among patients with substance use disorders. Substance Abuse Treatment, Prevention, & Policy. 2007;2:4. KQ2E4a. [PMC free article: PMC1781072] [PubMed: 17222348]
24.
Jeong SW, Kim JD, Woo HY, et al. Impact of adherence to peginterferon-ribavirin combination therapy in chronic hepatitis C patients on achieving a sustained virologic response. Korean Journal of Hepatology. 2009 Sep;15(3):338–49. KQ2E7. [PubMed: 19783883]
25.
Kawaguchi Y, Mizuta T, Takahashi K, et al. High-dose vitamins E and C supplementation prevents ribavirin-induced hemolytic anemia in patients with chronic hepatitis C. Hepatology Research. 2007 May;37(5):317–24. KQ1E4a, KQ2E4a, KQ3E4a, KQ4E4a. [PubMed: 17441803]
26.
Kevans D, Farrell G, Hopkins S, et al. Haematological support during peg-interferon therapy for HCV-infected haemophiliacs improves virological outcomes. Haemophilia. 2007 Sep;13(5):593–98. KQ2E1. [PubMed: 17880449]
27.
Kogure T, Ueno Y, Fukushima K, et al. Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan. World Journal of Gastroenterology. 2008;14(47):7225–30. KQ2E8. [PMC free article: PMC2776881] [PubMed: 19084938]
28.
Krook AL, Stokka D, Heger B, et al. Hepatitis C treatment of opioid dependants receiving maintenance treatment: results of a Norwegian pilot study. Eur Addict Res. 2007;13(4):216–21. KQ1E1, KQ4E1. [PubMed: 17851243]
29.
Larrey D, Salse A, Pageaux GP, et al. Effects of systematic nurse-provided therapeutic education on adherence and efficiency of PEG-interferon-ALPHA2A (PEGASYS®)ribavirin treatment in chronic hepatitis C (PEGOBS protocol) Journal of Hepatology. 2008;48(Suppl 1):S300. KQ1E2, KQ3E2, KQ4E2.
30.
Larrey D, Salse A, Ribard D, et al. Education by a Nurse Increases Response of Patients With Chronic Hepatitis C to Therapy With Peginterferon-alpha2a and Ribavirin. Clinical Gastroenterology and Hepatology. 2011;9(9):781–85. KQ4E2. [PubMed: 21683161]
31.
Lebray P, Nalpas B, Vallet-Pichard A, et al. The impact of haematopoietic growth factors on the management and efficacy of antiviral treatment in patients with hepatitis C virus. Antiviral Therapy. 2005;10(6):769–76. KQ1E7, KQ3E7. [PubMed: 16218177]
32.
Mak C, Heft SM, Amkraut H, et al. Compliance as an explanatory variable in Hepatitis-C. Drug Information Journal. 2001;35(4):1351–61. KQ2E1.
33.
Malaguarnera M, Vacante M, Bertino G, et al. The supplementation of acetyl-L-carnitine decreases fatigue and increases quality of life in patients with hepatitis C treated with pegylated interferon-alpha 2b plus ribavirin. Journal of Interferon and Cytokine Research. 2011;31(9):653–59. KQ1E2. [PubMed: 21923249]
34.
Mangia A, Dalgard O, Minerva N, et al. Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon alpha-2b and ribavirin. Alimentary Pharmacology & Therapeutics. 2010 Jun;31(12):1346–53. KQ2E1. [PubMed: 20222909]
35.
Manolakopoulos S, Deutsch MJ, Anagnostou O, et al. Substitution treatment or active intravenous drug use should not be contraindications forantiviral treatment in drug userswith chronic hepatitis C. Liver International. 2010;30(10):1454–60. KQ1E4a, KQ2E4a. [PubMed: 20846344]
36.
Marino EL, Alvarez-Rubio L, Miro S, et al. Pharmacist intervention in treatment of patients with genotype 1 chronic hepatitis C. Journal of Managed Care Pharmacy. 2009 Mar;15(2):147–50. KQ1E2, KQ3E2, KQ4E2. [PubMed: 19236128]
37.
McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002 Oct;123(4):1061–69. KQ1E2, KQ2E2. [PubMed: 12360468]
38.
Missiha S, Heathcote J, Arenovich T, et al. Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. American Journal of Gastroenterology. 2007 Oct;102(10):2181–88. KQ2E4a. [PubMed: 17640318]
39.
Morasco BJ, Rifai MA, Loftis JM, et al. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. Journal of Affective Disorders. 2007 Nov;103(1–3):83–90. [Erratum appears in J Affect Disord. 2009 Feb;113(1–2):201] KQ1E4a, KQ3E4a, KQ4E2. [PubMed: 17292481]
40.
Nudo CG, Wong P, Hilzenrat N, et al. Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C. Canadian Journal of Gastroenterology. 2006 Sep;20(9):589–92. KQ3E4a. [PMC free article: PMC2659944] [PubMed: 17001400]
41.
Raptopoulou-Gigi M, Tsantoulas D, Vafiadi I, et al. The effect of adherence to therapy on sustained response in daily or three times a week interferon alpha-2b plus ribavirin treatment of naive and nonresponder chronic hepatitis C patients. Journal of Viral Hepatitis. 2005;12(1):91–95. KQ2E4a. [PubMed: 15655054]
42.
Ridruejo E, Adrover R, Cocozzella D, et al. Efficacy, tolerability and safety in the treatment of chronic hepatitis C with combination of PEG-Interferon - Ribavirin in daily practice. Annals of Hepatology. 2010 Jan;9(1):46–51. KQ2E8. [PubMed: 20308722]
43.
Robaeys G, Van VH, Mathei C, et al. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. European Journal of Gastroenterology & Hepatology. 2006 Feb;18(2):159–66. KQ2E4a. [PubMed: 16394797]
44.
Rodis JL, Kibbe P. Evaluation of medication adherence and quality of life in patients with hepatitis C virus receiving combination therapy. Gastroenterol Nurs. 2010 Sep;33(5):368–73. KQ3E2. [PubMed: 20890160]
45.
Saab S. Academic perspectives on hepatitis C treatment adherence. Gastroenterology and Hepatology. 2009;5(3 Suppl 9):6–7. KQ4E5.
46.
Saito H, Tada S, Ebinuma H, et al. Role of erythrocytes as a reservoir for ribavirin and relationship with adverse reactions in the early phase of interferon combination therapy for chronic hepatitis C virus infections. Journal of Clinical Microbiology. 2006 Oct;44(10):3562–68. KQ2E4a. [PMC free article: PMC1594781] [PubMed: 17021083]
47.
Satapathy SK, Lingisetty CS, Proper S, et al. Equally poor outcomes to pegylated interferon-based therapy in African Americans and Hispanics with chronic hepatitis C infection. J Clin Gastroenterol. 2010 Feb;44(2):140–45. KQ2E2. [PubMed: 19826275]
48.
Schaefer M, Hinzpeter A, Mohmand A, et al. Hepatitis C treatment in “difficult-to-treat” psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology. 2007;46:991–98. KQ2E2. [PubMed: 17668880]
49.
Sezaki H, Suzuki F, Kawamura Y, et al. Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Digestive Diseases & Sciences. 2009 Jun;54(6):1317–24. KQ2E8. [PubMed: 18958621]
50.
Sharvadze L, Tsertsvadze T, Gochitashvili N, et al. Ifn/Rbv treatment induced anemia and its correction with epoetin alpha in patients with hepatitis C. Georgian Medical News. 2006;8(137):62–65. KQ3E2, KQ4E2. [PubMed: 16980747]
51.
Sharvadze L, Tsertsvadze T, Gochitashvili N, et al. Ifn/Rbv treatment induced anemia and its correction with epoetin alpha in patients with hepatitis C. Georgian Medical News. 2006;8(137):62–5. KQ3E2, KQ4E2. [PubMed: 16980747]
52.
Shehab TM, Fontana RJ, Oberhelman K, et al. Effectiveness of interferon alpha-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice. Clinical Gastroenterology & Hepatology. 2004 May;2(5):425–31. KQ2E4a. [PubMed: 15118982]
53.
Shiffman ML, Salvatore J, Hubbard S, et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology. 2007 Aug;46(2):371–9. KQ1E1. [PubMed: 17559152]
54.
Shin SR, Sinn DH, Gwak G-Y, et al. Risk factors for relapse in chronic hepatitis C patients who have achieved end of treatment response. Journal of gastroenterology and hepatology. 2010;25(5):957–63. KQ2E2. [PubMed: 20546450]
55.
Sola R, Galeras JA, Montoliu S, et al. Poor response to hepatitis C virus (HCV) therapy in HIV- and HCV-coinfected patients is not due to lower adherence to treatment. AIDS Research & Human Retroviruses. 2006 May;22(5):393–400. KQ2E4a. [PubMed: 16706615]
56.
Soriano V, Miralles C, Berdun MA, et al. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin. Antiviral Therapy. 2007;12(4):469–76. KQ2E2. [PubMed: 17668555]
57.
Stainbrook TR. Maximizing hepatitis C treatment adherence in the community setting. Gastroenterology and Hepatology. 2009;5(3 Suppl 9):8–10. KQ1E5, KQ3E5, KQ4E5.
58.
Sylvestre DL, Clements BJ, Malibu Y. Cannabis use improves retention and virological outcomes in patients treated for hepatitis C. European Journal of Gastroenterology & Hepatology. 2006 Oct;18(10):1057–63. KQ1E4a, KQ2E4a, KQ3E4a, KQ4E4a. [PubMed: 16957511]
59.
Sylvestre DL, Clements BJ. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. European Journal of Gastroenterology & Hepatology. 2007 Sep;19(9):741–47. KQ2E4a. [PubMed: 17700258]
60.
Talal AH, Liu RC, Zeremski M, et al. Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin. Journal of Acquired Immune Deficiency Syndromes: JAIDS. 2011 Nov 1;58(3):261–68. KQ1E2. [PMC free article: PMC3386143] [PubMed: 21876446]
61.
Taylor LE, Bowman SE, Chapman S, et al. Treatment for hepatitis C virus genotype 1 infection in HIV-infected individuals on methadone maintenance therapy. Drug & Alcohol Dependence. 2011 Jul 1;116(1–3):233–37. KQ1E2. [PMC free article: PMC4212315] [PubMed: 21177046]
62.
Viener M, Gill PV, Jan SA. Utilization patterns and compliance associated with hepatitis C agents in a managed care population. Manag Care Interface. 2005;18(11):25–28. KQ3E4a.
63.
Watanabe T, Konishi I, Shigematsu S, et al. Sustained virological response of patients with hepatitis C virus genotype 2 depends on pegylated interferon compliance. Hepatol Res. 2011 Aug;41(8):722–30. KQ2E1. [PubMed: 21682826]
64.
Weiss JJ, Bhatti L, Dieterich DT, et al. Hepatitis C patients’ self-reported adherence to treatment with pegylated interferon and ribavirin. Alimentary Pharmacology & Therapeutics. 2008 Aug 1;28(3):289–93. KQ2E5. [PMC free article: PMC2891196] [PubMed: 19086329]
65.
Yamada G, Iino S, Okuno T, et al. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors. Clinical Drug Investigation. 2008;28(1):9–16. [Erratum appears in Clin Drug Investig. 2008;28(4):210] KQ2E7. [PubMed: 18081356]

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (1.0M)

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...